23andMe Raises More Than $22 million in Series C Financing

23andMe published a press release earlier this morning regarding the outcome of our Series C financing round. The full text is copied below.


Mountain View, Calif. —  23andMe, Inc., a leading personal genetics company, announced today the closing of its Series C financing. The company raised a total of more than $22 million of funding from a new investor, Johnson & Johnson Development  Corporation, and current investors — including New Enterprise Associates and Google  Ventures.

“We believe this round of financing will help us achieve our goal of dramatically accelerating the pace of research and could ultimately make health care research and health care delivery more efficient,” said Anne Wojcicki, chief executive officer of  23andMe.

23andMe is actively recruiting for several key positions within the company. Available  positions are listed on the company’s website at https://www.23andme.com/about/jobs/.

This press release does not constitute or form part of, and should not be construed as an offer or an invitation to sell or issue, or the solicitation of any offer to buy or subscribe for, any securities.

About 23andMe
23andMe, Inc. is a leading personal genetics company dedicated to helping individuals  understand their own genetic information through DNA analysis technologies and web-based interactive tools. The company’s Personal Genome Serviceâ„¢ enables individuals  to gain deeper insights into their ancestry and inherited traits. The vision for 23andMe  is to personalize healthcare by making and supporting meaningful discoveries through  genetic research. 23andMe, Inc., was founded in 2006, and the company is advised  by a group of renowned experts in the fields of human genetics, bioinformatics and  computer science. More information is available at www.23andme.com.


Media Contacts

Rubenstein Communications
1345 Ave of the Americas
New York, NY 10105

Jane Rubinstein | 212-843-8287 | [email protected]
Rachel Nagler | 212-843-8017 | [email protected]
Adam Isserlis| 212-843-8024 | [email protected]